<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172012</url>
  </required_header>
  <id_info>
    <org_study_id>2019/1025</org_study_id>
    <nct_id>NCT04172012</nct_id>
  </id_info>
  <brief_title>Use of Probiotics to Reduce Infections, Death and ESBL Colonisation</brief_title>
  <acronym>ProRIDE</acronym>
  <official_title>Use of Probiotics to Reduce Infections and Death and Prevent Colonization With Extended-spectrum Beta-lactamase Producing Bacteria, Among Newborn Infants in Haydom and Surrounding Area, Tanzania, a Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Haydom Lutheran Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UiT The Arctic University of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Muhimbili University of Health and Allied Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the effect of oral probiotic treatment to newborns on preventing
      hospitalizations, death and colonization with Extended-spectrum beta-lactamase-producing Gram
      negative bacteria. Half of the babies will receive 4 weeks treatment with an oral mixture of
      the probiotic Labinic (R) while the other half will receive a placebo mixture.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies show that probiotics given to prematurely born babies prevents sepsis and is widely
      used in the western world for this purpose. Probiotics consists of one or more normal
      gut-bacteria. A large study in India showed that giving probiotics to full-born babies
      reduced hospitalizations and morbidity. This study investigates giving a probiotic mixture
      with different combination of bacteria, Lactobacillus acidophilus, Bifidobacterium infantis
      and Bifidobacterium breve, for a longer duration (4 weeks instead of 7 days).

      Infections with antibiotic-resistant bacteria is a major threat to health-care world-wide,
      and sepsis/severe infection caused by such bacteria is a major cause of neonatal death. The
      study hypothesis is that giving probiotics to newborns prevents them from getting colonized
      with antibiotic-resistant bacteria, such as Extended-spectrum beta-lactamase-producing
      Enterobacteriaceae (ESBL-PE). By preventing colonization with ESBL-PE, we may prevent severe
      infections such as sepsis, and thereby also prevent death.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Placebo-controlled double-blinded randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigational product (probiotic) and placebo product have both been produced by the same manufacturer and is delivered in identical bottles.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome hospitalization and death</measure>
    <time_frame>6 months from inclusion</time_frame>
    <description>Primary outcome is hospitalization and/or death of study subject</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ESBL colonization</measure>
    <time_frame>6 months</time_frame>
    <description>Colonization with Extended-spectrum beta-lactamase-producing Enterobacteriaceae as detected by fecal swab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study subjects receive probiotic mixture for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study subjects receive placebo mixture for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Labinic (R) probiotic mixture</intervention_name>
    <description>Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo mixture</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy newborn infants with a birth weight equal or above 2.0 kgs, will be included
             in the study between 0-3 days of life.

          -  Newborn infants have to come from families who are long-term or permanent residents in
             the defined catchment area for this trial (30 km radius from HLH) in Tanzania.

          -  Parents are able and willing to complete study visit (including required study
             procedures) schedules over the six months proposed follow-up, which also includes
             hospitalizations required for compliance of this study protocol.

          -  Parents agrees for the child not to participate in another study during the study
             period

          -  Children less than one year admitted to hospital with suspected infection, not
             included in the RCT, will be included in a sub-study. A separate inclusion form is
             prepared for these children.

        Exclusion Criteria:

          -  Birth weight below 2 kg

          -  Other health problems/illness, obvious congenital malformations.

          -  Parents not consenting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Langeland, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Langeland, MD, PhD</last_name>
    <phone>+4741616450</phone>
    <email>nina.langeland@uib.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjorn Blomberg, MD, PhD</last_name>
    <phone>+4793262119</phone>
    <email>bjorn.blomberg@uib.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Haydom Lutheran Hospital</name>
      <address>
        <city>Babati</city>
        <state>Manyara</state>
        <country>Tanzania</country>
      </address>
    </facility>
    <contact>
      <last_name>Joshua G Gidabayda, MD, MMed</last_name>
      <phone>+255784995669</phone>
      <email>joggs_2003@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Panigrahi P, Parida S, Nanda NC, Satpathy R, Pradhan L, Chandel DS, Baccaglini L, Mohapatra A, Mohapatra SS, Misra PR, Chaudhry R, Chen HH, Johnson JA, Morris JG, Paneth N, Gewolb IH. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017 Aug 24;548(7668):407-412. doi: 10.1038/nature23480. Epub 2017 Aug 16. Erratum in: Nature. 2017 Nov 29;:.</citation>
    <PMID>28813414</PMID>
  </reference>
  <reference>
    <citation>Esaiassen E, Hjerde E, Cavanagh JP, Pedersen T, Andresen JH, Rettedal SI, Støen R, Nakstad B, Willassen NP, Klingenberg C. Effects of Probiotic Supplementation on the Gut Microbiota and Antibiotic Resistome Development in Preterm Infants. Front Pediatr. 2018 Nov 16;6:347. doi: 10.3389/fped.2018.00347. eCollection 2018.</citation>
    <PMID>30505830</PMID>
  </reference>
  <reference>
    <citation>Tellevik MG, Blomberg B, Kommedal Ø, Maselle SY, Langeland N, Moyo SJ. High Prevalence of Faecal Carriage of ESBL-Producing Enterobacteriaceae among Children in Dar es Salaam, Tanzania. PLoS One. 2016 Dec 9;11(12):e0168024. doi: 10.1371/journal.pone.0168024. eCollection 2016.</citation>
    <PMID>27936054</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tanzania</keyword>
  <keyword>East Africa</keyword>
  <keyword>Antimicrobial resistance</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Extended Spectrum Beta-Lactamase Producing Bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

